Investing

Sizzling Buy-Rated Biotechs Highlight 5 Top Stocks Under $10

Puma Biotechnology

This is another micro-cap biotech that could be an outstanding idea for aggressive investors looking for names in the space. Puma Biotechnology Inc. (NASDAQ: PBYI) is a biopharmaceutical company focused on the development and commercialization of products to enhance cancer care in the United States and internationally.

The company’s drug candidates include PB272 neratinib (oral) for the adjuvant treatment of adult patients with early-stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for the use of neratinib in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer; and PB272 (neratinib, oral) for HER2 mutation-positive solid tumors.

Puma Biotechnology has a license agreement with Pfizer and sublicense agreement with Specialised Therapeutics Asia, CANbridge Biomed, Pint Pharma International, Knight Therapeutics, Pierre Fabre Medicament and Bixink Therapeutics.

Citigroup recently upgraded the stock and has an $11 price target. The consensus target is $8.63. The stock closed trading at $6.05 on Friday.

Surrozen

This stock was cut in half over the past month, but it has started to bounce back nicely. Surrozen Inc. (NASDAQ: SRZN) is a biotechnology company that discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair and regeneration. It is developing tissue-specific antibodies to engage the body’s existing biological repair mechanisms with potential application across various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas and central nervous system.

Surrozen’s products in the pipeline include SZN-043, which stimulates hepatocyte regeneration, improves liver function and reduces fibrosis; and SZN-1326, a bi-specific full-length human antibody that directly modulates Wnt signaling in target tissue by binding to particular Frizzled and LRP receptors that are highly expressed in intestinal crypts.

BofA Securities started coverage recently with an $11 price target. The shares were last seen at $6.32 on Friday, much closer to the post-IPO low of $5.49 than the high of $14.00.


These are five stocks for aggressive investors looking to get share count leverage on companies that have sizable upside potential. While not suited for all investors, they are not penny stocks with absolutely no track record or liquidity, and major Wall Street firms have research coverage.